[시장보고서]국소 분절 사구체 경화증(FSGS) 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)

국소 분절 사구체 경화증(FSGS) 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)

Focal Segmental Glomerulosclerosis Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

상품코드 : 1420963

리서치사 : Transparency Market Research

발행일 : 2023년 12월

페이지 정보 : 영문 163 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,795

￦ 8,627,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,795

￦ 13,093,000

PDF (Multi-user License)

PDF 보고서를 동일 부서 5명이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste가 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,795

￦ 17,560,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

샘플 요청 목록에 추가

국소 분절 사구체 경화증(FSGS) 시장 - 보고서의 범위

TMR의 세계 국소 분절 사구체 경화증(FSGS) 시장에 대한 보고서는 과거와 현재의 성장 동향과 2023년부터 2031년까지의 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻을 수 있는 기회를 조사했습니다. 이 보고서는 전 세계 국소 분절 사구체 경화증(FSGS)에 대한 수익을 제공합니다. 2023년을 기준 연도, 2031년을 예측 연도로 간주하여 2017년부터 2031년까지 시장을 분석합니다. 이 보고서는 2023년부터 2031년까지 전 세계 국소 국소 분절 사구체 경화증(FSGS) 시장의 복합 연간 성장률(CAGR%)도 제공합니다.

이 보고서는 광범위한 조사를 통해 작성되었으며, KOL(Key Opinion Leader), 업계 리더 및 오피니언 제조업체를 인터뷰하는 1차 조사에서 분석가들이 주요 오피니언 리더, 업계 리더 및 오피니언 제조업체를 인터뷰하고, 주요 기업의 제품 문헌, 연례 보고서, 보도 자료 및 보도자료를 참조하는 2차 조사를 통해 국소 분절 사구체 경화증(FSGS) 시장을 이해하고자 했습니다. 제품 문헌, 연례 보고서, 보도 자료 및 관련 문서에 대한 참조를 통해 국소 국소 분절 사구체 경화증(FSGS) 시장을 이해합니다.

시장 현황
2023년 시장 가치	5억 3,850만 달러
2031년 시장 가치	9억 5,620만 달러
CAGR	6.5%

이 보고서는 세계 국소 분절 사구체 경화증(FSGS) 시장의 경쟁 환경에 대해 자세히 조사했습니다. 세계 분절성 국소 분절 사구체 경화증(FSGS) 시장에서 활동하는 주요 기업이 확인되었으며, 이들 각각은 다양한 속성 측면에서 프로파일링됩니다. 기업 프로파일, 재무 상태, 최근 개발, SWOT는 이 보고서에 소개된 세계 국소 분절 사구체 경화증(FSGS) 시장의 기업 속성입니다.

시장 기업 - 경쟁 매트릭스(기업 Tier 및 규모별)
시장 점유율 분석 : 기업별(2022년)
기업 개요
- Variant Pharmaceuticals, Inc.
- ChemoCentryx, Inc.
- Travere Therapeutics
- AbbVie, Inc.
- Novartis AG
- Pfizer, Inc.
- AstraZeneca plc.
- Sanofi SA
- GlaxoSmithKline plc.
- Teva Pharmaceutical Industries Ltd.

LSH

영문 목차

영문목차

Focal Segmental Glomerulosclerosis Market - Scope of Report

TMR's report on the global focal segmental glomerulosclerosis market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global focal segmental glomerulosclerosis market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global focal segmental glomerulosclerosis market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the focal segmental glomerulosclerosis market.

Market Snapshot
Market Value in 2023	US$ 538.5 Mn
Market Value in 2031	US$ 956.2 Mn
CAGR	6.5%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global focal segmental glomerulosclerosis market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global focal segmental glomerulosclerosis market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global focal segmental glomerulosclerosis market.

The report delves into the competitive landscape of the global focal segmental glomerulosclerosis market. Key players operating in the global focal segmental glomerulosclerosis market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global focal segmental glomerulosclerosis market profiled in this report.

Key Questions Answered in Global focal segmental glomerulosclerosis Market Report:

What is the sales/revenue generated by focal segmental glomerulosclerosis across all regions during the forecast period?
What are the opportunities in the global focal segmental glomerulosclerosis market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2031?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

Focal Segmental Glomerulosclerosis Market - Research Objectives and Research Approach

The comprehensive report on the global focal segmental glomerulosclerosis market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global focal segmental glomerulosclerosis market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global focal segmental glomerulosclerosis market.

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Focal Segmental Glomerulosclerosis Market

4. Market Overview

4.1. Introduction
- 4.1.1. Disease Type Definition
- 4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global Focal Segmental Glomerulosclerosis Market Analysis and Forecast, 2017-2031

5. Key Insights

5.1. Pipeline Analysis
5.2. Key Disease Type/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry

6. Global Focal Segmental Glomerulosclerosis Market Analysis and Forecast, by Disease Type

6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Disease Type, 2017-2031
- 6.3.1. Primary Focal Segmental Glomerulosclerosis
- 6.3.2. Secondary Focal Segmental Glomerulosclerosis
6.4. Market Attractiveness Analysis, by Disease Type

7. Global Focal Segmental Glomerulosclerosis Market Analysis and Forecast, by Disease Management

7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Disease Management, 2017-2031
- 7.3.1. Diagnosis
  - 7.3.1.1. Kidney Biopsy
  - 7.3.1.2. Creatinine Test
  - 7.3.1.3. Others
- 7.3.2. Treatment
  - 7.3.2.1. Drug Therapy
  - 7.3.2.2. Dialysis
  - 7.3.2.3. Kidney Transplant
7.4. Market Attractiveness Analysis, by Disease Management

8. Global Focal Segmental Glomerulosclerosis Market Analysis and Forecast, by Region

8.1. Key Findings
8.2. Market Value Forecast, by Region, 2017-2031
- 8.2.1. North America
- 8.2.2. Europe
- 8.2.3. Asia Pacific
- 8.2.4. Latin America
- 8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region

9. North America Focal Segmental Glomerulosclerosis Market Analysis and Forecast

9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast, by Disease Type, 2017-2031
- 9.3.1. Primary Focal Segmental Glomerulosclerosis
- 9.3.2. Secondary Focal Segmental Glomerulosclerosis
9.4. Market Value Forecast, by Disease Management, 2017-2031
- 9.4.1. Diagnosis
  - 9.4.1.1. Kidney Biopsy
  - 9.4.1.2. Creatinine Test
  - 9.4.1.3. Others
- 9.4.2. Treatment
  - 9.4.2.1. Drug Therapy
  - 9.4.2.2. Dialysis
  - 9.4.2.3. Kidney Transplant
9.5. Market Value Forecast, by Country, 2017-2031
- 9.5.1. U.S.
- 9.5.2. Canada
9.6. Market Attractiveness Analysis
- 9.6.1. By Disease Type
- 9.6.2. By Disease Management
- 9.6.3. By Country

10. Europe Focal Segmental Glomerulosclerosis Market Analysis and Forecast

10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Disease Type, 2017-2031
- 10.3.1. Primary Focal Segmental Glomerulosclerosis
- 10.3.2. Secondary Focal Segmental Glomerulosclerosis
10.4. Market Value Forecast, by Disease Management, 2017-2031
- 10.4.1. Diagnosis
  - 10.4.1.1. Kidney Biopsy
  - 10.4.1.2. Creatinine Test
  - 10.4.1.3. Others
- 10.4.2. Treatment
  - 10.4.2.1. Drug Therapy
  - 10.4.2.2. Dialysis
  - 10.4.2.3. Kidney Transplant
10.5. Market Value Forecast, by Country/Sub-region, 2017-2031
- 10.5.1. Germany
- 10.5.2. U.K.
- 10.5.3. France
- 10.5.4. Italy
- 10.5.5. Spain
- 10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
- 10.6.1. By Disease Type
- 10.6.2. By Disease Management
- 10.6.3. By Country/Sub-region

11. Asia Pacific Focal Segmental Glomerulosclerosis Market Analysis and Forecast

11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Disease Type, 2017-2031
- 11.3.1. Primary Focal Segmental Glomerulosclerosis
- 11.3.2. Secondary Focal Segmental Glomerulosclerosis
11.4. Market Value Forecast, by Disease Management, 2017-2031
- 11.4.1. Diagnosis
  - 11.4.1.1. Kidney Biopsy
  - 11.4.1.2. Creatinine Test
  - 11.4.1.3. Others
- 11.4.2. Treatment
  - 11.4.2.1. Drug Therapy
  - 11.4.2.2. Dialysis
  - 11.4.2.3. Kidney Transplant
11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
- 11.5.1. China
- 11.5.2. Japan
- 11.5.3. India
- 11.5.4. Australia & New Zealand
- 11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
- 11.6.1. By Disease Type
- 11.6.2. By Disease Management
- 11.6.3. By Country/Sub-region

12. Latin America Focal Segmental Glomerulosclerosis Market Analysis and Forecast

12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Disease Type, 2017-2031
- 12.3.1. Primary Focal Segmental Glomerulosclerosis
- 12.3.2. Secondary Focal Segmental Glomerulosclerosis
12.4. Market Value Forecast, by Disease Management, 2017-2031
- 12.4.1. Diagnosis
  - 12.4.1.1. Kidney Biopsy
  - 12.4.1.2. Creatinine Test
  - 12.4.1.3. Others
- 12.4.2. Treatment
  - 12.4.2.1. Drug Therapy
  - 12.4.2.2. Dialysis
  - 12.4.2.3. Kidney Transplant
12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.5.1. Brazil
- 12.5.2. Mexico
- 12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
- 12.6.1. By Disease Type
- 12.6.2. By Disease Management
- 12.6.3. By Country/Sub-region

13. Middle East & Africa Focal Segmental Glomerulosclerosis Market Analysis and Forecast

13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Disease Type, 2017-2031
- 13.3.1. Primary Focal Segmental Glomerulosclerosis
- 13.3.2. Secondary Focal Segmental Glomerulosclerosis
13.4. Market Value Forecast, by Disease Management, 2017-2031
- 13.4.1. Diagnosis
  - 13.4.1.1. Kidney Biopsy
  - 13.4.1.2. Creatinine Test
  - 13.4.1.3. Others
- 13.4.2. Treatment
  - 13.4.2.1. Drug Therapy
  - 13.4.2.2. Dialysis
  - 13.4.2.3. Kidney Transplant
13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.5.1. GCC Countries
- 13.5.2. South Africa
- 13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
- 13.6.1. By Disease Type
- 13.6.2. By Disease Management
- 13.6.3. By Country/Sub-region

14. Competition Landscape

14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
- 14.3.1. Variant Pharmaceuticals, Inc.
  - 14.3.1.1. Company Overview
  - 14.3.1.2. Disease Type Portfolio
  - 14.3.1.3. SWOT Analysis
  - 14.3.1.4. Financial Overview
  - 14.3.1.5. Strategic Overview
- 14.3.2. ChemoCentryx, Inc.
  - 14.3.2.1. Company Overview
  - 14.3.2.2. Disease Type Portfolio
  - 14.3.2.3. SWOT Analysis
  - 14.3.2.4. Financial Overview
  - 14.3.2.5. Strategic Overview
- 14.3.3. Travere Therapeutics
  - 14.3.3.1. Company Overview
  - 14.3.3.2. Disease Type Portfolio
  - 14.3.3.3. SWOT Analysis
  - 14.3.3.4. Financial Overview
  - 14.3.3.5. Strategic Overview
- 14.3.4. AbbVie, Inc.
  - 14.3.4.1. Company Overview
  - 14.3.4.2. Disease Type Portfolio
  - 14.3.4.3. SWOT Analysis
  - 14.3.4.4. Financial Overview
  - 14.3.4.5. Strategic Overview
- 14.3.5. Novartis AG
  - 14.3.5.1. Company Overview
  - 14.3.5.2. Disease Type Portfolio
  - 14.3.5.3. SWOT Analysis
  - 14.3.5.4. Financial Overview
  - 14.3.5.5. Strategic Overview
- 14.3.6. Pfizer, Inc.
  - 14.3.6.1. Company Overview
  - 14.3.6.2. Disease Type Portfolio
  - 14.3.6.3. SWOT Analysis
  - 14.3.6.4. Financial Overview
  - 14.3.6.5. Strategic Overview
- 14.3.7. AstraZeneca plc.
  - 14.3.7.1. Company Overview
  - 14.3.7.2. Disease Type Portfolio
  - 14.3.7.3. SWOT Analysis
  - 14.3.7.4. Financial Overview
  - 14.3.7.5. Strategic Overview
- 14.3.8. Sanofi S.A.
  - 14.3.8.1. Company Overview
  - 14.3.8.2. Disease Type Portfolio
  - 14.3.8.3. SWOT Analysis
  - 14.3.8.4. Financial Overview
  - 14.3.8.5. Strategic Overview
- 14.3.9. GlaxoSmithKline plc.
  - 14.3.9.1. Company Overview
  - 14.3.9.2. Disease Type Portfolio
  - 14.3.9.3. SWOT Analysis
  - 14.3.9.4. Financial Overview
  - 14.3.9.5. Strategic Overview
- 14.3.10. Teva Pharmaceutical Industries Ltd.
  - 14.3.10.1. Company Overview
  - 14.3.10.2. Disease Type Portfolio
  - 14.3.10.3. SWOT Analysis
  - 14.3.10.4. Financial Overview
  - 14.3.10.5. Strategic Overview

한글목차

국소 분절 사구체 경화증(FSGS) 시장 - 보고서의 범위

목차

제1장 서문

제2장 전제조건과 조사 방법

제3장 주요 요약 : 세계 시장

제4장 시장 개요

제5장 주요 인사이트

제6장 세계 시장 분석과 예측 : 질환 유형별

제7장 세계 시장 분석과 예측 : 질병 관리별

제8장 세계 시장 분석과 예측 : 지역별

제9장 북미 시장 분석과 예측

제10장 유럽 시장 분석과 예측

제11장 아시아태평양 시장 분석과 예측

제12장 라틴아메리카 시장 분석과 예측

제13장 중동 및 아프리카 시장 분석과 예측

제14장 경쟁 구도